Can analysts adopt a bullish outlook for MacroGenics, Inc. (NASDAQ:MGNX)?

July 20, 2018 - By Jacob Reddy

Investors sentiment increased to 1.79 in Q1 2018. Its up 0.68, from 1.11 in 2017Q4. It increased, as 13 investors sold MacroGenics, Inc. shares while 25 reduced holdings. 30 funds opened positions while 38 raised stakes. 31.74 million shares or 12.30% more from 28.26 million shares in 2017Q4 were reported.
Granite Point Mngmt Ltd Partnership invested in 40,000 shares. Stifel reported 19,766 shares or 0% of all its holdings. Prelude Cap Limited holds 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX) for 254 shares. Wasatch Advsrs reported 1.02 million shares. Massachusetts-based Hall Laurie J Trustee has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). The Oregon-based Hood River Ltd Co has invested 0.91% in MacroGenics, Inc. (NASDAQ:MGNX). Trexquant Inv Limited Partnership holds 40,776 shares or 0.07% of its portfolio. Dimensional Fund Advisors Limited Partnership holds 289,484 shares or 0% of its portfolio. Tudor Investment Et Al has invested 0.03% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Alliancebernstein Ltd Partnership reported 41,700 shares stake. California State Teachers Retirement Sys holds 0% or 51,580 shares in its portfolio. Bnp Paribas Arbitrage Sa invested in 7,236 shares. State Common Retirement Fund owns 50,553 shares. Rhumbline Advisers has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Kepos Capital Lp reported 0.02% stake.

Since January 24, 2018, it had 0 insider purchases, and 6 insider sales for $998,021 activity. Risser Eric Blasius sold $31,080 worth of stock. Karrels James had sold 5,000 shares worth $155,000 on Monday, March 5.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 5 analysts covering MacroGenics (NASDAQ:MGNX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. MacroGenics had 5 analyst reports since January 23, 2018 according to SRatingsIntel. SunTrust maintained it with “Buy” rating and $31.0 target in Tuesday, January 23 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, March 14. The rating was initiated by Leerink Swann with “Buy” on Friday, April 6. Below is a list of MacroGenics, Inc. (NASDAQ:MGNX) latest ratings and price target changes.

31/05/2018 Broker: Evercore Rating: Outperform New Target: $33 Initiates Coverage On
06/04/2018 Broker: Leerink Swann Rating: Buy New Target: $35.0000 Initiate
14/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $18 New Target: $26 Maintain
05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38 Initiates Coverage On
23/01/2018 Broker: SunTrust Rating: Buy New Target: $31.0 Maintain

The stock decreased 0.20% or $0.05 during the last trading session, reaching $22.18. About 39,556 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 19.62% since July 20, 2017 and is uptrending. It has outperformed by 7.05% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $936.25 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.